Simcere Pharma expects FY revenue to jump 16,017.6
TL;DR
Simcere Pharma reported strong H1 2022 results with revenue up 27.3% to RMB 2.7 billion, driven by a 44.8% surge in innovative drug sales. Key growth came from its CNS portfolio, including Sanbexin®, and the company plans to accelerate R&D and expand in high-need therapeutic areas.
Tags
Simcere Pharma expects FY revenue to jump 16,017.6
Simcere Pharmaceutical Reports Strong H1 2022 Performance, Outlines Growth Strategy
Simcere Pharmaceutical Group Limited (2096.HK) has demonstrated robust growth in its innovative drug portfolio, driving revenue and market share expansion. For the first half of 2022, the company reported operating revenue of RMB 2.7 billion, reflecting a 27.3% year-over-year increase. Net profit for the period was estimated at RMB 390 million after adjusting for non-recurring items. Notably, innovative drug revenue surged 44.8% year-over-year to RMB 1.767 billion, accounting for 65.4% of total revenue—a record high—highlighting the company's successful transition to an innovation-driven business model.
The company's CNS portfolio, led by Sanbexin® (Edaravone and Dexborneol concentrated solution for injection), has been a key growth driver. Launched in 2020, Sanbexin® has benefited 860,000 patients nationwide and contributed to a 74.7% year-over-year revenue increase in the CNS segment. A sublingual tablet formulation of Sanbexin is currently in Phase 3 trials, with 914 patients enrolled ahead of schedule. The product is expected to complement the injectable version and address unmet needs in CNS disease management.
Simcere's R&D pipeline remains a strategic focus, with 60+ innovative drug projects in development and 16 potential candidates in clinical trials. Two advanced programs include SIM0417, an anti-SARS-CoV-2 drug targeting the 3CL protease, and Cosela® (Trilaciclib), a first-in-class myelo-protection therapy approved in July 2022. The latter was developed through a licensing-in collaboration and achieved market approval in China in just 708 days—a record for such initiatives.
Looking ahead, Simcere plans to accelerate NDA submissions for its pipeline candidates and explore new indications for existing therapies. While the company has not disclosed specific 2024 revenue forecasts beyond a projected 0.2–0.6% year-over-year increase, its emphasis on differentiated innovation and expanding CNS market leadership positions it to capitalize on China's evolving pharmaceutical landscape.
With six global first-in-class drugs on the market and a diversified R&D strategy, Simcere continues to strengthen its competitive edge amid industry challenges such as national bulk-buy programs. Its focus on CNS, oncology, and autoimmune diseases aligns with high-unmet-need therapeutic areas, supporting long-term growth potential.
